Table 6.
Comparisons of trends in acquired non-susceptibility in Escherichia coli, Staphylococcus aureus, and Streptococcus pneumoniae
| Microbe | Type of non-susceptibility | Surveillance Area | Trends in proportions of non-susceptibility (Time period) | |
|---|---|---|---|---|
| E. coli | Gentamicin non-susceptibility | Levanger Hospital | 0.5% (2002–05) | 3.3% (2010–13) |
| Iceland | 2.9% (2010) | 4.1% (2013) | ||
| Norway | 0.6% (2003) | 7.7% (2014) | ||
| EU/EEA | 5.2% (2002) | 9.9% (2013) | ||
| Bulgaria | 15.8% (2003) | 32.1% (2013) | ||
| E. coli | Resistance to 3rd generation cephalosporins | Levanger Hospital | 0 (2002–05) | 1.7% (2010–13) |
| Norway | 1.5% (2008) | 5.8% (2014) | ||
| EU/EEA | 2.0% (2002) | 12.6% (2013) | ||
| Bulgaria | 24.8% (2010) | 39.6% (2013) | ||
| S. aureus | MRSA | Levanger Hospital | 0 (2002–05) | 1.0% (2010–13) |
| Norway | 0.3% (2002) | 0.8% (2014) | ||
| EU/EEA | 25.6% (2007) | 18.0% (2013) | ||
| Malta | 52.0% (2007) | 51.8% (2013) | ||
| Romania | 39.1% (2010) | 64.5% (2013) | ||
| S. pneumoniae | PNSP | Levanger Hospital | 0 (2002–05) | 3.0% (2010–13) |
| Netherlands | 2.0% (2010) | 1.1% (2013) | ||
| Norway | 0.9% (2002) | 5.5% (2014) | ||
| Cyprus | 41.7% (2010) | 40.0% (2013) | ||
MRSA, meticillin-resistant Staphylococcus aureus; PNSP, penicillin non-susceptible pneumococci
Proportions of non-susceptibility from the current study (Levanger Hospital) are compared with data from Norway (the national surveillance system [8, 30], the European Union/the European Economic Area (EU/EEA), and with countries which have extraordinary low or high proportions of non-susceptibility [7, 24, 25]